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Summary The treatment of breast cancer patients has changed rapidly in the past decade, but empirical data
at local and national level are scarce. Predicting the consequences of screening for primary treatment is
consequently difficult. The aim of this analysis of records on admissions to hospital of women with breast
cancer and/or for breast surgery (1975-90) together with a survey of all Dutch radiotherapy departments
(1986-88) is to show the change in breast-conserving therapy and other primary treatment before the start of
breast cancer screening in The Netherlands. There was a modest increase in breast-conserving therapy after
1981, coinciding with the first publication on its trial, followed by a sharp increase between 1985 and 1990,
after the second publication. At the end of that 5 year period, 36% of all women with newly diagnosed
invasive breast cancer underwent this type of surgery. Breast-conserving surgery is always followed by
radiotherapy, but there has been a clear reduction in post-operative radiation after mastectomy. The percent-
age of breast-conserving therapy is at present higher in The Netherlands than in the USA. Implementing the
Dutch screening programme will result in a maximum increase in breast-conserving therapy at national level of
34%, which stabilises at + 21%, or a 50% maximum increase at local level. The number of women treated by
mastectomy will ultimately decrease by 9%. Given the rapidity of change towards the use of breast-conserving
surgery, which is enhanced by screening, recent information will be needed in predicting capacity and assessing
whether screen-detected women are treated adequately.
The treatment of breast cancer patients has changed rapidly
in the past decade. Several trials have led to a better under-
standing of the possible results of different types of primary
treatment. Breast-conserving therapy, limited surgery fol-
lowed by high-dose radiation, has been shown to be as
effective as modified radical mastectomy for most operable
patients (Veronesi et al., 1981). For mastectomy patients,
routine post-operative radiotherapy is now usually con-
sidered unnecessary (Edland, 1988; Harris & Hellman, 1988).
It could be assumed that treatment practice would be in-
fluenced by the information from these trials, but empirical
data at national and local level are scarce in most countries
(Farrow et al., 1992; Chouillet et al., 1994).
At the same time, countries have started to implement
breast cancer screening, as trials have shown that a reduction
in mortality from breast cancer can be expected for screened
women aged 50-69. The impact on the number and type of
surgical procedures and radiotherapy will be great as a result
of both the temporary increase in the number of women
detected with breast cancer and the increase in early cancers
(de Koning et al., 1990). Bottlenecks in capacity are expected,
but there is a lack of empirical data to support this
hypothesis.
As we were especially uncertain about the development of
breast-conserving therapy (outside a screening programme),
we have analysed data on the actual number and type of
primary treatments for breast cancer in The Netherlands in
the years before the start of nationwide screening. In this
report, we present the trend in primary treatment for the
period 1975-90, and the expected influence of breast cancer
screening in the near future. Emphasis is placed on surgery
and radiotherapy, and especially on the comparison between
breast-conserving therapy and mastectomy, and on post-
operative radiotherapy after mastectomy. The findings are
compared with the scarce international data, from the USA,
and may serve for planning and evaluation of both breast
cancer treatment and screening, and for the interpretation of
the impact of results from new trials.
Materials and methods
Two independent sources provided data on the use ofsurgery
and/or radiotherapy for women with breast cancer. The
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number of different types of surgical procedures was deter-
mined by analysing all the available records on hospital
admissions in The Netherlands for women with breast cancer
and/or for breast surgery for the period 1975-90 (Centre for
Health Care Information). Coverage of recording increased
in this period from 83% of all admissions (in 1975) to,
respectively, 89%, 90%, 94%, 94%, 95%, 94% (in 1981),
97%, 98%, 99% (in 1984-89) to 99.7% in 1990. The records
included the patient's age, whether it was a first or subse-
quent admission, a detailed description of surgical proce-
dures, number of nursing days, diagnoses at discharge and
residence after discharge. The accuracy of recording surgical
procedures can be assumed to be high, since its registration is
based on a uniform and detailed classification of surgery
codes (Classification of Surgery, 1977) with 25 different types
of breast surgery. It is being applied in all hospitals by
trained personnel with national guidelines for recording
breast-conserving therapy. Only in 1990, a revised (and
extended) coding system was introduced.
Data on radiation treatment are not recorded centrally in
The Netherlands. A questionnaire was therefore sent to all 20
Dutch radiotherapy departments, concerning the number of
female breast cancer patients who had had radiotherapy and
the different types of radiotherapy in the years 1986-88.
Sixteen departments responded, and additional information
on the total patient population of all 20 departments enabled
us to -extrapolate figures for the whole population.
Except for one regional cancer register, no incidence data
were available from a complete national record of cancer.
The clinical (age-specific) breast cancer incidence was based
on the national registration of first hospital admissions and
on an additional 15% of breast cancers in the 70 + group,
assumed to be underrepresented in incidence figures based on
hospital admissions (e.g. for primary hormonal treatment).
National data that have recently become available for the
year 1990 confirm this (NCR, 1994).
All primary breast cancer treatment could be divided into
treatment for women with ductal carcinoma in situ (DCIS)
(treatment by either local excision, local excision plus
radiotherapy or total mastectomy) and that for women with
invasive carcinoma. The latter group is treated by breast-
conserving therapy with an external booster, breast-
conserving therapy with an iridium implant, total mastec-
tomy, total mastectomy with post-operative radiotherapy (all
usually with axillary dissection), a combination of treatment
modalities for stage IIIB tumours or primary hormonal treat-
ment (tamoxifen); see also Table I. For these treatment
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Table I Estimated numbers and percentages of new breast cancer treatments in The
Netherlands in 1990 without mass screening
Treatment Numbers % Main sources
Primary treatment DCIS
Local excision 115 30 Hospital; trial
Local excision + radiotherapy 115 30 Hospital; trial
Total mastectomy 150 40 Hospital
Total 380 100
Primary treatment invasive carcinoma
Breast-conserving therapy, external booster 2,400 30 Hospital; radiotherapy
Breast-conserving therapy, iridium implant 475 6 Hospital; radiotherapy
Mastectomy, no radiotherapy 2,400 30 Hospital; radiotherapy
Matectomy and radiotherapy 1,525 19 Hospital; radiotherapy
Primary tamoxifen 375 5 Model
Treatment locally advanced disease (IIIB) 400 5 Registry
Stage IV treatment 450 55 Registry
Total 8,025 100
Total female breast cancer incidence 8,405a
Adjuvant tamoxifen 1,750 26b Survey
Adjuvant chemotherapy 750 1 1b Survey
Total 2,500 37
aIn 1994, data from the national cancer register on the 1990 newly registered cancer cases
became available (NCR, 1994); adjusting for the 355 screen-detected cases, national incidence is
approximately 8,575, 2% higher than previously estimated. bPercentage related to invasive
carcinomas, except stages IIIB and IV and already primary tamoxifen.
options, and for adjuvant systemic treatment, we estimated
the number of women treated in The Netherlands in 1990.
The year 1990 was chosen for practical reasons, since it
coincided with the start of nationwide screening.
Combining these figures with the clinical incidence and
stage distribution of breast cancer, and the treatment
guidelines, we predicted the chance of being treated by each
modality for four groups of women: those with clinically
diagnosed ductal carcinoma in situ; those with invasive car-
cinomas smaller than 10mm in diameter; those with car-
cinomas larger than or equal to 10mm but smaller than
20mm; and those with invasive carcinomas of 20mm and
more. The axillary lymph node status corresponding with
these stages was taken into account. With screening, there is
a shift towards smaller sizes and towards a more favourable
lymph node status. Women with screen-detected cancer have
a lower percentage of axillary lymph node metastases than
women with clinically diagnosed cancer, even within the same
tumour size category (de Koning et al., 1990; Tabiar et al.,
1992). Lymph node and distant metastases status for screen-
detected cancers was determined from the Utrecht and Nij-
megen experimental screening projects, and for clinically
diagnosed cancers from the Utrecht 'non-screened' group.
The chances of treatment modality per tumour size category
were also predicted for women with screen-detected breast
cancer (see Appendix).
The MISCAN breast cancer model (van Oortmarssen et
al., 1990a) was used to predict the number of women in the
four tumour categories with and without breast cancer
screening. The disease model is based on a three-state
division of the development of invasive carcinoma and one
DCIS state. Key parameters on the mean duration of the
screen-detectable preclinical states and the sensitivity were
derived from results of the Health Insurance Plan (HIP)
analysis (van Oortmarssen et al., 1990b) and from a new
analysis of all results from the Dutch screening trials in
Nijmegen and Utrecht (de Koning et al., 1991). This method
has been shown to be useful for predicting the effects and
cost of screening in other countries, e.g. Australia and Ger-
many, using country-specific data if available (Carter et al.,
1993; Beemsterboer et al., 1994) or using data from other
screening projects (Boer et al., 1994). In this report, the
influence of screening on the change in treatments will be
shown for a policy of 2-yearly screening for women aged
50-69 and an attendance rate of 70%, which started in 1990
and will be fully implemented around 1994. The projected
changes in management in the years when screening is
gradually being introduced might be influenced by so-called
autonomous changes, such as a continuous rise in the use of
breast-conserving therapy independent of the detection of
more smaller lesions. Additionally, a survey among 40 Dutch
breast cancer experts was used to estimate the possible trend
in primary treatment in the 1990s if there were no screening
programme. Three variants were distinguished in the
forecasts: one in which the number of women treated by
breast-conserving therapy will continue to follow the forecast
increase to 1995. In this scenario, we assume - from the data
analysed - that this technology is further spread during these
years. In a second variant the proportion will remain at the
1990 level (treatment criteria are stable) and will only be
influenced by the increase in breast cancer incidence. A third,
intermediate variant was also distinguished.
Results
Primary surgery and/or radiotherapy 1978-90
The main treatment choice for women with operable invasive
breast cancer is between conservation or more radical treat-
ment. In the period 1978-80, the number of recorded admis-
sions for limited breast surgery for breast cancer was very
small, and probably not all related to breast-conserving
therapy (Figure la). Even in the preceding 3 years there were
as many as 135 such admissions recorded annually, although
this treatment was not really standard practice in those years,
as far as we know. From 1981, coinciding with the publica-
tion of the first results of the randomised trial on quadran-
tectomy, there was a relatively small absolute increase in
breast-conserving therapy. However, a rapid and steady in-
crease from 1985 on is visible, the year the first results of the
second randomised trial were published. Ultimately, 2,823
hospital admissions for limited breast cancer surgery were
recorded in 1990 (including approximately 200 screen-
detected cases).
The independent survey among radiotherapy departments
confirms the rapid and steady increase in the number of




























Figure 1 a, Number of admissions for women with breast cancer
and limited breast surgery, 1978-90, The Netherlands: 94.3%
coverage in 1978, 94.0% in 1981, 98.9% in 1985, 99.7% in 1990.
b, Annual number of breast cancer patients treated by (high-
dose) radiation after limited breast surgery (breast-conserving
therapy), as registered in each radiotherapy department (+), as a
percentage of the total annual number of all patients radiated
(not only breast cancer patients). A Mean per cent of all depart-
ments, The Netherlands 1986-88. On average, total (n) 23,350.
Total numbers in 1987 or 1988 differ only 1% from those in
1986, and may therefore be used as a steady baseline for the
individual department and years. The decrease in post-operative
radiotherapy after mastectomy would complicate comparisons if
the percentage was related to all breast patients.
the years 1986-88. Figure lb shows the annual number of
breast cancer patients treated by (high-dose) radiation after
limited breast surgery (as a percentage of the total number of
all patients with radiotherapy) in the different departments.
Although there is variation between centres, the increase in
the average total number equals that seen in records of
hospital admissions (see also Figure 2). In these years 1,330,
1,679 and 2,015 treatments respectively were recorded in 16
departments. If these centres are assumed to be a represen-
tative sample of all 20 Dutch centres, the estimate for the
whole of The Netherlands would be 2,400 treated women in
1988. About 15% of these treatments are followed by an
iridium booster, the others by an external booster.
The differences in numbers between the two sources are
relatively small (Figure 2). Although there has been no link-
age between the two data sources, given the 99% coverage of
hospital records and the similar trend when analysing the
radiotherapy data, we can conclude that both sources on
surgery and radiotherapy are in agreement with each other.
The hospital records probably slightly underestimate the
breast-conserving therapy as each year another 200 admis-
sions are coded as 'biopsy and axillary dissection' (not
included in the above estimates), whereas the radiotherapy
data might slightly overestimate its numbers owing to a less
uniform recording and no distinction between invasive and
non-invasive cancer. We therefore used the average estimate
for the present situation (Figure 2, line C), that approxi-
mately 2,900 women had been treated conservatively in 1990,
which is 36% of all women with newly diagnosed invasive
breast carcinoma in The Netherlands.
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Figure 2 Annual numbers ofpatients with invasive breast cancer
treated by limited surgery followed by radiotherapy (breast-
conserving therapy) in The Netherlands, 1983-2000. (A) accord-
ing to national hospitals' records; (B) according to radiotherapy
departments; (C) without screening, 1990 level (no trend); (D)
with screening (base level C); (E) without screening, 1992 level
(including time trend); (F) with screening (base level E) (G)
maximum number with screening (including time trend and
expert opinion). *Number of patients treated by radiation after
mastectomy (radiation departments).
Except for a small proportion of women treated by
primary hormonal treatment or by primary radiotherapy, the
remaining women are treated with breast ablation, mostly by
modified radical mastectomy. Whether this should be fol-
lowed by radiotherapy on a routine basis is a matter of
dispute. Fifteen radiotherapy departments recorded a clear
decrease in the number of women treated by radiation after a
mastectomy, from 2,126 in 1986 to 1,518 in 1988 (Figure 2,
line*). The decrease in 1987-88 is less evident than in the
previous 2 years, and it remains difficult to establish a
definite trend. Nevertheless, oni the basis of these data, we
assume a total of 1,525 post-mastectomy irradiations in 1990,
which corresponds to 39% of the breast cancer patients
treated by mastectomy. Table I summarises the estimated
numbers of treatment modalities applied in 1990.
Possible developments in 1990-2000 independent ofmass
screening
Further developments are to be expected in the near future
on at least the criteria for performing breast-conserving
therapy and for radiotherapy after mastectomy, thereby pos-
sibly resulting in autonomous changes independent of screen-
ing. Experts envisage an increase in the proportion of breast
cancer patients treated by breast-conserving therapy in the
next 5-10 years, from the present 35% up to 50% of all
female breast cancer patients, if there were no screening
programme. This would mean continuation of the line seen
in 1985-90. They foresee room for a further spreading of the
technology throughout the country as a result of more and
better multidisciplinary treatment protocols, change of treat-
ment criteria, greater demand from women and/or a
generally earlier diagnosis of breast cancer. This expected
increase will inevitably level off, as there will come a time
when all patients who are eligible for conservative surgery
and want it are actually treated in this fashion. In practice,
the upper limit of tumour size tends to decrease owing to
unsatisfactory cosmetic results in larger tumours. When fac-
tors such as the presence of extensive ductal carcinoma in situ
around the invasive part, the refusal of women or doctors
and the tumour size/breast volume ratio are taken into
account, we can assume that 50% of all women with
operable invasive breast cancer (but excluding stage IlIb, not
stage IV, not primary tamoxifen) might be treated conserv-
atively. This represents approximately 42% of all newly diag-
nosed invasive breast cancer patients per year, which would
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Figure 3 Annual change (%) in breast-conserving therapy (a)
and breast ablation (b) at local and national level resulting from
the screening of women aged 50-69 every 2 years (percentage
compared with situation without mass screening in that year).
National level (U): gradual build-up of all screening units over 5
years. Regional level ( =): consequences surrounding one
screening unit with approximately 10,000 screens per year starting
in 1990 (2 year build-up).
Influence ofmass screening in 1990-2000
The introduction of mass screening has a profound impact
on these estimates. Implementation will always result in a
temporary increase in the number of persons detected who
have the disease. Most evident is the increase in detected
cancers at the first (prevalent) screening. The start of the
Dutch breast cancer screening programme in 1990 resulted in
a rise in the number of newly diagnosed cases of 355. A
maximum 17% (= 1,450 cancers) increase is expected in the
year 1993. From 1996 onwards, the total yearly number of
diagnosed breast cancers will be 3.5% higher than the
number without screening (de Koning et al., 1991).
The main consequences of earlier diagnosis for treatment
practice are shown in Figure 3, taking 1990 as a stable
situation. Since almost all treatments depend on at least
tumour type and size and/or lymph node metastases, we may
expect differences to occur for all therapeutic aspects. Most
important is the shift from mastectomy to breast-conserving
therapy owing to the detection of cancer at an earlier stage.
At a national level, we would expect a steady increase in
breast-conserving therapy up to a 34% increase (+ 1,025) in
1994. After that, the increase will stabilise at approximately
+ 21% (+ 640 per year) compared with the number of treat-
ments expected without screening each year (Figure 2, line D,
and Figure 3a). The number of women treated by mastec-
tomy will ultimately decrease by 9% (-370 per year). The
decrease in the number of mastectomies does not equal the
increase in breast-conserving therapy because of the higher
incidence and detection of early lesions resulting from screen-
ing. All primary treatments that will eventually show a de-
crease owing to the more favourable stage distribution of
screen-detected cancers still show an increase in the build-up
period of screening. This is a result of both the temporary
increase in women diagnosed as having cancer and the less
favourable stage distribution in which these cancers are
detected at the first screening round compared with subse-
quent rounds.
At the regional level, the temporary increase in the number
of breast-conserving therapies may be much more dramatic,
since the regional build-up periods of screening are even
shorter than the nationwide build-up. Figures 3a and b also
show the percentage changes for the region surrounding a
centre with 10-12,000 screens a year that started in 1990: the
number of women who undergo breast-conserving therapy
increases by 50% to begin with, but does not last as
long.
Discussion
Increase in breast-conserving therapy
The number of breast cancer patients treated conservatively
has increased rapidly in The Netherlands since the mid-
1980s, coinciding with the appearance of results of the
second trial (Fisher et al., 1985). It is clear that earlier
estimates based on 1983-85 admission data only are out-
dated as a result of this change (de Koning et al., 1990).
Given the high coverage of (detailed) recording, and the
similarity in data from two independent sources, it is highly
unlikely that the observed trend has been influenced by any
recording biases. However, the increase is not infinite, as
trials have shown that breast-conserving therapy is only as
effective as modified radical mastectomy for localised small
cancers, and several studies have shown definitive contrain-
dications (Bartelink et al., 1988; van Dongen et al., 1992).
Data from The Netherlands Cancer Institute suggest that
approximately 55% of all operable patients are appropriate
candidates for breast-conserving therapy (Hooning et al.,
1991). The present analysis shows two important aspects in
terms of the quality of breast cancer treatment in The
Netherlands: breast-conserving surgery is always followed by
radiation treatment and the actual number of women treated
conservatively is rapidly approaching the number that would
be expected on the basis of oncological data and protocols.
The extent to which breast-conserving therapy has been
adopted in other countries is rarely described. Only recently,
information became available from parts of the USA (Far-
row et al., 1992). In nine areas, the percentage of white
women (n = 18,399 in 4 years) with localised invasive breast
cancer treated by breast-conserving surgery increased from
approximately 22% in the period 1983-84 to 33% in
1985-86, which seems to be an extremely early increase in
this technology. It is known that the publication in 1985 of
the results of the US randomised clinical trial of breast-
conserving surgery led to a temporary peak in some districts
in 1985, followed by a decline (Lazovich et al., 1991). A
publication on a much larger group of 41,680 breast cancer
patients treated in nine other areas in the USA in 1988 -
31% of all cases in that year - reveals only 25% of these
patients being treated by partial mastectomy (Osteen et al.,
1992). It is apparent that there are strong regional differences
in the USA, and that the often heard proposition that
Europe follows developments in the USA after a time lag
does not seem to be borne out by the data on breast-
conserving therapy in The Netherlands. The percentage has
been higher in the latter country in recent years. Secondly,
although there was a nationwide temporal trend towards the
increasing use of radiation after breast-conserving surgery in
the USA, the situation there was quite different from the
situation in The Netherlands, where all women received
radiotherapy after limited surgery.
Future treatment changes
The uncertainties are more or less concentrated in the upper
ranges of our results. Of course, future practice in radiation
treatment after mastectomy would seem to be the biggest
unknown factor. It might be said that we are unable to
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implemented in the next few years. Almost all experts
thought it very likely that the percentage of women that
would undergo radiation treatment after mastectomy would
decrease in the next 5-10 years (without taking account of a
screening programme). It is likely that even less radiation
treatment will be given after radical mastectomy, but that it
will continue to decrease both for women with screen-
detected cancers and for those with clinically diagnosed
cancers. The influence of new treatment trials or new results
of ongoing trials have, of course, not yet been taken into
account (Veronesi et al., 1993). Most of these apply to
treatment schedules in which a less serious intervention is
compared with the present treatments described in our
results.
Even the influence of mass screening on breast-conserving
therapy alters if we assume that the results of treatment trials
had not yet influenced some clinicians' and/or women's de-
cisions. If we assume that the increase in breast conservation
will continue until 1995, mainly as a result of a general
broadening of criteria, we might expect that both women
with breast cancer diagnosed clinically and women with
screen-detected breast cancer would be treated more fre-
quently by conservation in the nearby future (Figure 2, line
G). An important advantage of this analysis is the prediction
of treatment changes before a screening programme has
started, which can be used to estimate the required capacity.
The initial increases in breast-conserving surgery, mastectomy
and DCIS treatment as a result of screening may be relatively
small in terms of the total number of surgical procedures, but
represent more than 7.5% of present breast surgery. Together
with the additional increase in biopsies, the early years of
screening will result in an additional average increase in
breast surgery at national level of 15-20%. Even more
important would be to forecast changes for radiotherapy
services, as investment in possible new machinery takes time.
Considering both the increase in primary radiation treatment
due to screening and the decreases in treatment for advanced
disease (de Koning et al., 1992), the total number of
radiotherapeutic sessions would increase by 5% in 1994,
which is 22% of all sessions for breast cancer. This increase
will initially have to be dealt with using existing facilities.
Expectations compared w1'ithfirst observations
There is almost no literature on the predicted treatment
consequences of implementing screening. This seems a logical
result of the lack of national data on applied treatment
modalities for breast cancer in most countries where screen-
ing is not carried out, and of the lack of a method in which
the detailed changes induced by screening, in terms of
number, stage and period of detected cancers, are taken into
account (as in this study). The first published results on
changes in breast-conserving therapy due to screening sup-
port our analysis at the local level. Although numbers are
small, in the Enschede region breast-conserving therapy in-
creased by 50-70% compared with the situation without
screening (Boekema et al., 1992). Sixty-one per cent of
screen-detected (invasive) breast cancer patients underwent
conservation surgery, compared with 43% of patients diag-
nosed outside the screening. Recent data from another large
region, the IKA region, show that approximately 40% of
operable (invasive) screen-detected patients underwent con-
servative surgery (1990-92), but there is wide variation
between hospitals (17-71%) (P.C.M. van Velthoven, per-
sonal communication, 1993). But, again, the difference
induced by screening is striking, as in 1989 only approxi-
mately 30% of the breast cancer patients were treated conser-
vatively (without screening). The projections of screening in
general, as we have made for The Netherlands, appear to
resemble closely the actual performance of screening in the
first years; the attendance rate and the number and stages of
cancers detected for the 180,000 newly invited women com-
pare favourably with the expected values (NETB, 1994).
We will be following the actual changes in the next years,
at both national and regional levels. Important regional
differences should be monitored when screening is imple-
mented and, together with the stage distribution, these
findings may function as a guide as to whether screened
women with breast cancer are treated adequately. Detailed
information on treatment changes in respect of mass screen-
ing are also crucial for estimating the influence on the quality
of life, and for adjusting the expected future reduction in
breast cancer mortality, if necessary. In particular, the in-
creasing use of adjuvant systemic treatment and consequent
mortality reduction may interact with the achievable reduc-
tion arising from earlier detection of cancer.
In conclusion, the rapidity of change towards the use of
breast-conserving surgery, like the change from radical
mastectomy to modified radical mastectomy during the
1970s, will be enhanced by the additional increase due to
mass screening.
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Appendix
(a) Chance of breast-conserving therapy for operable women
with invasive breast cancer (not stage IlIb, not stage IV, not
primary tamoxifen): 1990 level (no trend)
Size of tumour (mm)
< 10 10-19 > 20
Clinically diagnosed 0.7 0.6 0.3
Screen-detected 0.8 0.7 0.5
(b) Chance of post-operative radiotherapy for operable women
with invasive carcinoma treated by mastectomy: 1990 level (no
trend)
Size of tumour (mm)
<10 10-19 >20
Clinically diagnosed 0.30 0.33 0.41
Screen-detected 0.25 0.29 0.35